§ 4.117 Schedule of ratings—hemic and lymphatic systems.

### Anemia

- **Hypochromic-microcytic and megaloblastic anemia:**
  - Hemoglobin 5gm/100ml or less, with findings such as heart failure or dyspnea at rest
  - Hemoglobin 7gm/100ml or less, with findings such as dyspnea on mild exertion, cardiomegaly, tachycardia
  - Hemoglobin 8gm/100ml or less, with findings such as dyspnea on exertion, cardiac symptoms
  - Hemoglobin 10gm/100ml or less, with findings such as dyspnea on exertion, reduced activity, cardiovascular symptoms

#### Rating

- **100:** Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months
- **60:** Requiring transfusion of platelets or red cells at least once per year but less than once every three months, or; infections recurring at least once per year but less than every three months
- **30:** Requiring continuous medication for control

**Note:** The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, rate on residuals.

### Polycythemia vera

- **100:** During periods of treatment with myelosuppressants and for three months following cessation of myelosuppressant therapy
- **40:** Stable, with or without continuous medical treatment
- **10:** Stable, without or without continuous medical treatment

**Note:** Rate complications such as hypertension, gout, stroke or thrombotic disease separately.

### Thrombocytopenia, primary, idiopathic or immune

- **100:** Platelet count of less than 20,000, with active bleeding, requiring treatment with medication and transfusions
- **70:** Platelet count between 20,000 and 70,000, not requiring treatment, without bleeding
- **30:** Stable platelet count between 70,000 and 100,000, without bleeding
- **0:** Stable platelet count of 100,000 or more, without bleeding

**Note:** Rate complications such as systemic infections with encapsulated bacteria separately.

### Spleen, injury of, healed

- **10:** Rate for any residuals

### Hodgkin’s disease

- **100:** With active disease or during a treatment phase
- **60:** Not controlled by treatment
- **30:** Requiring continuous treatment for control

**Note:** The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no recurrence, rate on residuals.

### Other neoplasms

- **60:** Benign neoplasms of the gynecological systems
  - Pelvic pain or heavy or irregular bleeding

**Note:** Diagnosis of endometriosis must be substantiated by laparoscopy.

### Other lymphatic disease

- **30:** Recurrence or metastasis, rate on residuals.

**Note:** Review for entitlement to special monthly compensation under § 3.350 of this chapter.

### Other lymphatic disease

- **20:** Splenectomy

**Note:** Rate complications such as systemic infections with encapsulated bacteria separately.

### Other lymphatic disease

- **10:** Spleen, injury of, healed.

**Note:** The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.
The Skin

§ 4.118 Schedule of ratings—skin.

A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805, as in effect before October 23, 2008, may request review under diagnostic codes 7800, 7801, 7802, 7804, and 7805, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran’s disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic codes 7800, 7801, 7802, 7804, and 7805. A request for review pursuant to this rulemaking will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review; however, in no case will the award be effective before October 23, 2008.

<table>
<thead>
<tr>
<th>Rating</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7800</td>
<td>Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other disfigurement of the head, face, or neck:</td>
</tr>
<tr>
<td>80</td>
<td>With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement</td>
</tr>
<tr>
<td>50</td>
<td>With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement</td>
</tr>
<tr>
<td>30</td>
<td>With visible or palpable tissue loss and either gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement</td>
</tr>
<tr>
<td>10</td>
<td>With one characteristic of disfigurement</td>
</tr>
<tr>
<td></td>
<td>Note (1):The 8 characteristics of disfigurement, for purposes of evaluation under § 4.118, are:</td>
</tr>
<tr>
<td></td>
<td>Scar 5 or more inches (13 or more cm.) in length</td>
</tr>
<tr>
<td></td>
<td>Scar at least one-quarter inch (0.6 cm.) wide at widest part</td>
</tr>
<tr>
<td></td>
<td>Surface contour of scar elevated or depressed on palpation</td>
</tr>
<tr>
<td></td>
<td>Scar adherent to underlying tissue</td>
</tr>
<tr>
<td></td>
<td>Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.)</td>
</tr>
<tr>
<td></td>
<td>Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in an area exceeding six square inches (39 sq. cm.)</td>
</tr>
<tr>
<td></td>
<td>Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.)</td>
</tr>
<tr>
<td></td>
<td>Skin indurated and inflexible in an area exceeding six square inches (39 sq. cm.)</td>
</tr>
</tbody>
</table>